Therapeutic Potential of Isoniazid in a Microbial-Induced Crohn’s Disease Model
Overview
Isoniazid administration in the TNFΔARE mouse model of Crohn’s-like ileitis significantly reduced both systemic and intestinal inflammation. This effect was associated with decreased colonization by segmented filamentous bacteria (SFB) and reduced formation of tertiary lymphoid organs, suggesting a novel mycobacterial-independent mechanism of action.
Background
Inflammatory bowel disease (IBD), including Crohn’s disease (CD), affects millions globally with limited treatment options. Anti-TNFα therapies like Infliximab have improved outcomes but pose risks for latent tuberculosis (TB) reactivation, necessitating prophylactic use of anti-tuberculoid drugs such as Isoniazid. While Isoniazid is primarily used to prevent TB activation, its potential effects on intestinal inflammation independent of TB infection remain unclear. The TNFΔARE mouse model, which mimics human CD-like ileitis, provides a platform to explore these effects.
Data Highlights
Parameter
Effect of Isoniazid
Behavioral Sickness (movement, climbing, rearing)
Significant protection from loss of function
Systemic Inflammation (cytokine levels)
Significant reduction
Intestinal Inflammation (terminal ileum)
Significant reduction
Colonization by SFB
Reduced epithelial colonization
Formation of Tertiary Lymphoid Organs
Diminished in ileal mesentery
Key Findings
Prophylactic Isoniazid (10 mg/kg/day) protects TNFΔARE mice from progressive sickness behaviors between 8-12 weeks of age.
Isoniazid significantly reduces systemic and local intestinal inflammation in the Crohn’s-like ileitis model.
The drug limits epithelial colonization by segmented filamentous bacteria (SFB), a known pathobiont linked to inflammation.
Reduction in inflammation correlates with decreased formation of precursor-tertiary lymphoid organs in the ileal mesentery associated with SFB-derived endospores.
TNFΔARE mice exhibit accelerated posttranscriptional decay of IL-22 mRNA, leading to diminished IL-22 protein and antimicrobial peptides; Isoniazid mitigates inflammation despite this defect.
Clinical Implications
Isoniazid may offer a novel therapeutic avenue for Crohn’s disease by modulating the intestinal microbiota and immune response independent of its anti-mycobacterial activity. This suggests potential benefits in limiting mucosal colonization by inflammatory pathobionts and reducing ectopic lymphoid organ formation, which are implicated in disease pathophysiology. Clinicians should consider these findings when managing patients with Crohn’s disease, especially those at risk for latent TB.
Conclusion
Isoniazid demonstrates a mycobacterial-independent capacity to attenuate intestinal and systemic inflammation in a Crohn’s disease mouse model by restricting pathobiont expansion and associated immune structures. These findings highlight its potential as a novel therapeutic strategy targeting microbial-driven inflammation in Crohn’s disease.
References
Kollias et al. 1999 -- Development of the TNFΔARE mouse model of Crohn’s-like ileitis
WHO 2020 -- Tuberculosis Preventative Therapy Guidelines
